Elucidata Finances Key Go-To-Market Initiatives With $5 Million Venture Investment

Biomedical Molecular Data Company Secures Pre-Series A Financing Round Led by IvyCap Ventures

Elucidata, a biomedical molecular data company, announced that it has closed a $5 million pre-Series A funding round led by IvyCap Ventures. The financing round also included participation from Hyperplane Venture Capital and several angel investors.

This new round of funding will enable Elucidata to capitalize on its position as a leading provider of structured biomedical molecular data to the life sciences industry. The company plans to use the funding to accelerate product development, expand its commercial efforts, and continue hiring world-class talent.

“In the pharma industry, biomedical data of drug discovery is increasing in diversity and volume at a rapid rate,” said Vikram Gupta, Founder and Managing Partner, IvyCap Ventures. “In this scenario, it gives us immense pleasure to collaborate with Elucidata which is driven by its vision of accelerating drug discovery. Their platform, Polly, makes a vast range of biological big data accessible and available to the scientists for machine learning.”

Recommended AI News: Who Do You Think You Are: Jewelry Edition

Elucidata is focused on developing Polly, a proprietary cloud platform for drug discovery. The company said that Polly is the largest repository of biomedical data designed for scientists trying to discover drugs. With Polly, scientists can get access to curated and analysis-ready data from over 100,000 biomedical datasets, a number that is doubling each quarter, accelerating data-driven discovery efforts.

“Multi-omics structured data on Polly have been used to identify promising therapeutic targets, biomarkers, patient segments, rank different chemical matters, among other things,” said Abhishek Jha, Co-founder and CEO, Elucidata. “As an industry, we’re just scratching the surface of how powerful molecular data can be when made FAIR. The strong backing from IvyCap Ventures and Hyperplane will amplify our ability to help our partners improve in their data-driven drug discovery.”

Recommended AI News: Arcturus Teams Up with Telecom Giant DOCOMO to Bring Volumetric Videos

Elucidata launched Polly in April 2019 and now has over 30 partners in industry and academia as its customers. In the past seven months, Elucidata has seen increased demand while expanding adoption at enterprise clients such as Genentech, TRV, Alnylam Therapeutics, and Agios.

“Hyperplane is proud to be partnered with Elucidata in their mission of enhancing the predictability and speed of drug discovery through their collaborative bioinformatics platform,” said Naimish Patel, Managing Partner, Hyperplane. “Having already demonstrated clear product-market fit and grown a strong base of top tier pharmaceutical and biotech customers, this new infusion of capital positions the company for accelerated market growth in the years to come.”

Elucidata was founded in 2015 by Jha, a University of Chicago and MIT graduate, IIT Delhi graduate Swetabh Pathak, and Dr. Richard Kibbey (MD PhD) at Yale School of Medicine.

Recommended AI News: DataTrace Unveils Access to Digitally Enhanced Historical New York Pre-ACRIS Images